Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the united states-Reference-Cited by-同舟云学术

Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the united states

Published:2009-05 Issue:5 Volume:31 Page:1092-1104
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Lyman Gary H.,Lalla Anjana,Barron Richard L.,Dubois Robert W.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference63 articles.

1. 2006 Update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline;Smith;J Clin Oncol.,2006

2. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer;Crawford;N Engl J Med.,1991

3. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy;Trillet-Lenoir;Eur J Cancer,1993

4. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer;Holmes;J Clin Oncol.,2002

5. A randomized doubleblind multicenter phase III study of fixed-dose singleadministration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy;Green;Ann Oncol.,2003

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness analysis of granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced febrile neutropenia in patients with breast cancer in Taiwan;PLOS ONE;2024-06-10

2. Cost-Effectiveness Analysis for Therapy Sequence in Advanced Cancer: A Microsimulation Approach with Application to Metastatic Prostate Cancer;Medical Decision Making;2023-10

3. Cost comparison of filgrastim versus pegfilgrastim and pegfilgrastim biosimilars for inpatient prophylaxis of febrile neutropenia;Journal of Oncology Pharmacy Practice;2022-12-21

4. Colony stimulating factors for prophylaxis of chemotherapy-induced neutropenia in children;Expert Review of Clinical Pharmacology;2022-08-03

5. Management costs of febrile neutropenia in oncology patients in a Tertiary care Hospital Care in Colombia;REV COLOMB CANCEROL;2022